Xellia Pharmaceuticals is a world leader in the development, manufacture and supply of fermented anti-infectives sold as active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) to the global pharmaceutical market. The company’s product range covers anti-infectives, treating certain serious and life-threatening bacterial and fungal infections; Xellia being the world leading supplier of vancomycin and colistimethate sodium (CMS).

We as a company are conscious of the role we play in ensuring responsible manufacturing, and stable and reliable supply of our products.

As we work towards the development of both new and improved drugs to help tackle the global crisis of AMR, we have advanced our focus on improving the efficacy and safety profile of anti-infectives as well as towards reducing the side effects of our existing products. Our pipeline reflects the development of a number of generic anti-infectives and furthermore a range of unique and proprietary products. First out will be line extensions based on improved formulations and drug device combinations.

Our success and strong market position is built upon more than 100 years’ of pharmaceutical industry experience. Supplying products to pharmaceutical companies in more than 70 countries and with more than 500 customers internationally, Xellia places a high regard on maintaining strong relationships with its customers and business partners. We aim to be the preferred partner for the global supply of anti-infective drugs for the critical care market.

Xellia Pharmaceuticals has, over the past years, made great progress in executing its strategy of forward integrating from API to FDF sales, and in 2016 FDF accounted for almost half of the company’s total revenues. Significant progress has been made with launches of new anti-infective products and investments in injectable capacity, most notably with the acquisition of the Cleveland based facility from Hikma Pharmaceuticals in 2015. A robust pipeline and significant injectable manufacturing capacity will ensure continued growth in the coming years.

Headquartered in Copenhagen, Denmark and owned by Novo A/S, Xellia has more than 1,350 employees globally. Xellia has state-of-the-art manufacturing sites located in the U.S., China, Denmark and Hungary; R&D sites in Norway and Croatia, and sales offices in China, Japan, India and the U.S.